DBS stock tops S$58 as Singapore bank rally rolls on; investors eye Feb 9 results

DBS stock tops S$58 as Singapore bank rally rolls on; investors eye Feb 9 results

DBS Group shares rose 0.6% to S$58.25 in Wednesday afternoon trade, after hitting S$58.80 and nearing a 52-week high. The Straits Times Index reached a record 4,765.29 earlier, led by gains in bank stocks. Analysts expect DBS to raise its quarterly dividend to 66 cents in 2026 and pay an extra 15 cents a share through 2027. Investors are watching net interest margins and potential changes in dividend policy.
7 January 2026
DroneShield stock cools after JPMorgan drops below 5% stake — what ASX:DRO investors watch next

DroneShield stock cools after JPMorgan drops below 5% stake — what ASX:DRO investors watch next

DroneShield shares fell 0.77% to A$3.89 Wednesday after surging 18.43% the previous session, with trading volume dropping by nearly half. A filing showed JPMorgan Chase & Co. and affiliates dropped below the 5% substantial holder threshold on Jan. 2. The company extended its partnership with the Australian Defence Force Drone Racing Team and promoted Louis Gamarra to chief commercial officer.
South32 stock rises on the ASX as copper hits record highs — what investors watch next

South32 stock rises on the ASX as copper hits record highs — what investors watch next

South32 shares closed up 1.6% at A$3.84 in Sydney, trading A$86.6 million in value. The move followed copper prices hitting $13,000 a ton in London, with analysts warning of a global deficit. South32 disclosed new and lapsed employee share rights in a routine filing. The company plans to idle its Mozal aluminium smelter in Mozambique by March, citing a failed power deal and a $60 million cost.
ANZ share price slides as sticky core inflation keeps RBA rate path in focus

ANZ share price slides as sticky core inflation keeps RBA rate path in focus

ANZ Group Holdings fell 1.5% to A$35.43, closing at its session low and underperforming the S&P/ASX 200, which rose 0.28%. The move followed flat November inflation data, keeping rate hike bets in play. Australia’s other major banks also closed lower. Interest-rate futures now price about a one-in-three chance of a Reserve Bank hike in February.
Fortescue stock pulls back from near 52-week high as iron ore rallies — what investors watch next

Fortescue stock pulls back from near 52-week high as iron ore rallies — what investors watch next

Fortescue Ltd shares slipped 0.18% to A$22.80 at Wednesday’s close, retreating from near a 52-week high as iron ore futures hit a five-month peak on strong Chinese steel demand. Australia’s CPI eased to 3.4% in November, tempering rate-hike bets. Investors await Fortescue’s December-quarter production report on Jan 22. The Reserve Bank of Australia next meets Feb. 2–3.
7 January 2026
Lynas Rare Earths stock jumps 14.5% as China-Japan export curb puts rare earth supply in focus

Lynas Rare Earths stock jumps 14.5% as China-Japan export curb puts rare earth supply in focus

Lynas Rare Earths shares surged 14.5% to A$15.06 after China imposed immediate export bans on “dual-use” items to Japan, raising concerns over rare earth supply. Japan’s government called the move “absolutely unacceptable” but said the scope was unclear. The S&P/ASX 200 closed up 0.15%. G7 finance ministers will meet Jan. 12 to discuss rare earth supply chains.
7 January 2026
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.01.2026

Sensex and Nifty opened lower on January 8, 2026, tracking declines in major global markets. Foreign portfolio investors pulled ₹16,848 crore from 15 sectors in late December, with FMCG and Financial Services seeing the largest outflows. IT sector recorded inflows. GIFT Nifty and Asian shares also pointed to a weak start.
7 January 2026

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop